What this study is
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.
What's being tested
- Spirometer
Intervention · DEVICE
Home spirometry will be conducted weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece).
- Oximeter
Intervention · DEVICE
Oxygen saturation levels will be measured daily using a pulse oximeter.
- Scale
Intervention · DEVICE
Weight will be measured weekly using a wireless scale provided by the study.
- ePROs (electronic patient reported outcomes)
Intervention · OTHER
Brief electronic symptom questionnaires will be completed through a secure app which will be downloaded on participant's phone.
Study details
- Sponsor
- University of California, San Francisco
- Conditions
- Fibrotic Interstitial Lung Disease · IPF and PPF · Lung Fibrosis Interstitial
- Enrolling
- 200 people
- Starts
- 2026-10-01
- Est. completion
- 2028-08-01
- Design
- Open-label, randomized, factorial
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 18 or older
- English speaking
- Have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for >10% of the ILD diagnoses seen at UCSF.
You can't join if
- Patients who are unable provide informed consent for any reason or are acutely ill.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of California, San Francisco
San Francisco, California, United States
- Yeji Lee · Contact415-353-9744Yeji.Lee@ucsf.edu
- Erica D Farrand, MD · Principal investigator
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 25-44428
Principal investigator
Erica Farrand, MD
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.